MeSH term
Frequency | Condition_Probility | Adolescent | 4 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 4 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Exons/genetics | 5 | 0.0 |
Female | 15 | 0.0 |
Heterozygote | 4 | 0.0 |
Humans | 37 | 0.0 |
Infant | 5 | 0.0 |
Introns/genetics | 3 | 0.0 |
Linkage (Genetics)/*genetics | 3 | 1.0 |
Male | 20 | 0.0 |
Molecular Sequence Data | 14 | 0.0 |
Mutation/*genetics | 3 | 0.0 |
Phenotype | 3 | 0.0 |
Protein-Tyrosine-Phosphatase/*genetics | 14 | 10.0 |
Research Support, Non-U.S. Gov't | 36 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
X Chromosome/*genetics | 7 | 2.0 |
Animals | 10 | 0.0 |
Cell Line | 4 | 0.0 |
Microscopy, Fluorescence | 3 | 0.0 |
*Mutation | 3 | 0.0 |
Myopathies, Structural, Congenital/*genetics | 3 | 75.0 |
Protein-Tyrosine-Phosphatase/*genetics/metabolism | 3 | 14.0 |
Research Support, U.S. Gov't, P.H.S. | 5 | 0.0 |
Amino Acid Sequence | 6 | 0.0 |
Binding Sites | 2 | 0.0 |
Exons | 6 | 0.0 |
Mutation | 6 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Tissue Distribution | 2 | 0.0 |
X Chromosome/genetics | 3 | 1.0 |
Phosphatidylinositol Phosphates/*metabolism | 2 | 6.0 |
Precipitin Tests | 2 | 0.0 |
Chromosome Mapping | 10 | 0.0 |
Frameshift Mutation | 3 | 0.0 |
Infant, Newborn | 9 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Polymorphism, Single-Stranded Conformational | 4 | 0.0 |
Sequence Deletion | 2 | 0.0 |
*X Chromosome | 17 | 1.0 |
Adult | 6 | 0.0 |
Chromosome Banding | 2 | 0.0 |
Heterozygote Detection | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Pedigree | 10 | 0.0 |
Syndrome | 3 | 0.0 |
Alleles | 3 | 0.0 |
Muscular Diseases/*genetics | 8 | 25.0 |
Gene Deletion | 3 | 0.0 |
*Linkage (Genetics) | 8 | 0.0 |
Muscles/pathology | 2 | 5.0 |
Protein-Tyrosine-Phosphatase/genetics | 2 | 6.0 |
Base Sequence | 8 | 0.0 |
Cloning, Molecular | 7 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Genes, Recessive | 2 | 0.0 |
Linkage (Genetics) | 7 | 0.0 |
Pregnancy | 2 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Genetic Markers | 7 | 0.0 |
Muscle Hypotonia/*genetics | 3 | 33.0 |
Muscle Weakness/*genetics | 2 | 66.0 |
*Point Mutation | 2 | 0.0 |
Polymorphism, Genetic | 2 | 0.0 |
*Gene Deletion | 2 | 0.0 |
Genitalia, Male/*abnormalities | 2 | 22.0 |
DNA, Complementary | 2 | 0.0 |
Rats | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Recombination, Genetic | 2 | 0.0 |
Comparative Study | 2 | 0.0 |
DNA Primers | 3 | 0.0 |
Mice | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Sex Chromosome Aberrations/*genetics | 2 | 3.0 |
Dosage Compensation (Genetics) | 2 | 1.0 |
In Vitro | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Time Factors | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
Phosphatidylinositols/*metabolism | 2 | 2.0 |
Protein-Tyrosine-Phosphatase/genetics/*metabolism | 2 | 4.0 |
Enzyme Activation | 2 | 0.0 |
Myopathies, Structural, Congenital/*genetics/pathology | 2 | 100.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
